<DOC>
	<DOCNO>NCT00809419</DOCNO>
	<brief_summary>The objective MERITAGE Trial evaluate safety efficacy focal delivery radiation treatment subfoveal choroidal neovascularization ( CNV ) associate wet age-related macular degeneration ( AMD ) patient require persistent injection Anti-VEGF therapy maintain adequate response treatment .</brief_summary>
	<brief_title>A Study NeoVista Ophthalmic System Treatment Subfoveal CNV Associated With Wet AMD Patients That Require Persistent Anti-VEGF Therapy</brief_title>
	<detailed_description>Therapeutic advance arena neovascular age-related macular degeneration ( AMD ) provide multiple treatment option disease . Brachytherapy study multiple clinical trial past many study show therapeutic benefit . Treatment radiotherapy anti-VEGF compound promise approach treat AMD . The current treatment neovascualar AMD involve multiple injection indefinite period time . This trial evaluate whether treatment brachytherapy reduce eliminate need continue injection .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Subjects must predominantly classic , minimally classic , occult classic lesion , determine Investigator , secondary AMD , total lesion size ( include blood , scar , neovascularization ) &lt; 12 total disc area ( 21.24 mm2 ) GLD â‰¤5.4 mm . Subjects must complete antiVEGF induction treatment , define first 3 month treatment . Following induction period , subject must require least 5 additional injection Avastin Lucentis 12 month precede enrollment , 3 additional injection Avastin Lucentis 6 month precede enrollment , give need basis . Subjects may previously receive Macugen , although must meet criterion Lucentis Avastin . Subjects must age 50 old Subjects prior concurrent subfoveal CNV therapy agent , surgery device ( exclude Macugen , Avastin , Lucentis ) include thermal laser photocoagulation ( without photographic evidence ) , photodynamic therapy , intravitreal subretinal steroid , transpupillary thermotherapy ( TTT ) Subjects underwent previous radiation therapy eye , head neck Subjects previously diagnose Type I Type II Diabetes Mellitus . Subjects DO NOT document diagnosis , retinal finding consistent Type I Type II Diabetes Mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Brachytherapy</keyword>
	<keyword>EpiRad</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>